Gliomas are the most common tumours of the central nervous system and the most
aggressive form is glioblastoma (GBM). Despite advances in treatment, patient survival …

Malignant gliomas are devastating tumours that frequently kill patients within 1 year of
diagnosis. The major obstacle to a cure is diffuse invasion, which enables tumours to …

Glioblastoma multiforme (GBM), an aggressive tumor that typically exhibits treatment failure
with high mortality rates, is associated with the presence of cancer stem cells (CSCs) within …

Glioblastoma is one of the most devastating cancers, in which tumor cell infiltration into
surrounding normal brain tissue confounds clinical management. This review describes …

Glutathione (GSH) and GSH‐related enzymes constitute the most important defense system
that protects cells from free radical, radiotherapy, and chemotherapy attacks. In this study …

Human glioblastoma (GBM) is a highly aggressive, invasive and hypervascularised
malignant brain cancer. Individual circulating tumour cells (CTCs) are sporadically found in …

Glioblastoma (GBM) is the most common and malignant form of primary brain tumor with a
median survival time of 14–16 months in GBM patients. Surgical treatment with …

Malignant tumors of the central nervous system (CNS) are among cancers with the poorest
prognosis, indicated by their association with tumors of high-level morbidity and mortality …

The poor response of glioblastoma to current treatment protocols is a consequence of its
intrinsic drug resistance. Resistance to chemotherapy is primarily associated with …

Background A shift from respiration to fermentation is a common metabolic hallmark of
cancer cells. As a result, glucose and glutamine become the prime fuels for driving the …